Kristev A, Sirakov V, Kostadinova I, Lukanov J
Department of Physics and Biophysics, University of Medicine, Plovdiv, Bulgaria.
Folia Med (Plovdiv). 1994;36(4):13-22.
Ethosuximide is an antiepileptic drug successfully used in the treatment of petit mal especially in childhood. Clinical investigations reveal that ethosuximide has a number of adverse side effects on the gastrointestinal tract (GIT) of patients which may include heaviness, anorexia, pains in the region of the stomach, accompanied sometimes with nausea and vomiting. In the present study we attempt to explain the mechanisms of some of the drug's adverse side effects using an experimental animal model. White rats were employed in the experiments during which they were treated daily with ethosuximide (100 mg/kg) for 100 days. We made use of the following methods in the study: 1. Contrast X-rays study of the gastrointestinal tract. 2. Recording of the bioelectric activity of isolated smooth muscle strips using the sucrose-gap method. 3. Recording of the contractile activity of isolated smooth muscle. Characteristic changes occurring after treatment of rats with ethosuximide include atony of the stomach and the intestines, hypertonus in separate duodenal segments, diminished peristaltic activity, and delayed passage at the 24th hour. The drug inhibits the spontaneous contractile activity of isolated smooth muscle strips from rat gastrointestinal tract. In some duodenal preparations is minimised in the presence of apamin, an inhibitor of Ca2+(-dependent) K+ channels (Ka+(Ca)), while in duodenal preparations this effect may undergo a reversion. In the presence of coffeine the action of ethosuximide on the smooth musculature of rat gastrointestinal tract is reduced significantly. We hypothesis that the observed functional changes in the gastrointestinal tract occur as a result of the hyperpolarizing effect of ethosuximide on the gastrointestinal musculature caused by the outcoming K+(CA)-efflux.
乙琥胺是一种成功用于治疗小儿癫痫小发作的抗癫痫药物,尤其适用于儿童。临床研究表明,乙琥胺对患者胃肠道有多种不良副作用,可能包括腹胀、厌食、胃部区域疼痛,有时还伴有恶心和呕吐。在本研究中,我们试图使用实验动物模型来解释该药物某些不良副作用的机制。实验采用白色大鼠,在100天内每天给它们注射乙琥胺(100毫克/千克)。我们在研究中使用了以下方法:1. 胃肠道的对比X射线研究。2. 使用蔗糖间隙法记录离体平滑肌条的生物电活动。3. 记录离体平滑肌的收缩活动。用乙琥胺治疗大鼠后出现的特征性变化包括胃和肠道无力、十二指肠各段张力亢进、蠕动活动减弱以及24小时时通过延迟。该药物抑制大鼠胃肠道离体平滑肌条的自发收缩活动。在一些十二指肠制剂中,在钙依赖性钾通道(Ka+(Ca))抑制剂蜂毒明肽存在的情况下这种作用最小化,而在十二指肠制剂中这种作用可能会逆转。在咖啡因存在的情况下,乙琥胺对大鼠胃肠道平滑肌组织的作用会显著降低。我们假设观察到的胃肠道功能变化是由于乙琥胺对胃肠道肌肉组织的超极化作用导致钾离子外流所致。